EMBRAER S.A.: Share Buyback Program
MATERIAL FACT EMBRAER S.A.Publicly Held CompanyCNPJ/MF: 07.689.002/0001-89NIRE: 353.003.257-67 SÃO JOSÉ DOS CAMPOS, Brazil, March 17, 2025 /PRNewswire/ —... Read more.
Thomson Reuters Announces Final Results of Exchange Offers and Consent Solicitations and Intention to File Replacement Base Shelf Prospectus
TORONTO, March 17, 2025 /PRNewswire/ — Thomson Reuters (TSX/Nasdaq: TRI), a global content and technology company, announced today the expiry of its previously... Read more.
Sabio Announces Audited 2024 Results, Achieves Record Revenues and Adjusted EBITDA Profitability
Strong revenue growth, leaner cost structure and strengthened balance sheet are enabling investments to drive 2025 growth Achieved record full-year consolidated... Read more.
NASA Space Day to Share Progress, Opportunities at Texas Capitol
HOUSTON, March 17, 2025 /PRNewswire/ — NASA is heading back to the state capitol in March for Space Day Texas, a recognition of achievements throughout Texas... Read more.
Microsoft responds to TRC Capital’s “mini-tender” offer
REDMOND, Wash., March 17, 2025 /PRNewswire/ — Microsoft Corp. has received notice of an unsolicited “mini-tender” offer by TRC Capital Investment... Read more.
FinVolution Group Announces Dividend Increase to US$0.277 per American Depositary Share, Up 17% Year-Over-Year
-Represents Approximately 21.5% Payout Ratio of Net Income for FY 2024--Marks seventh consecutive year of dividend declaration-–Revised Dividend Policy of... Read more.
FinVolution Group Announces New Share Repurchase Program Up To US$150 million
SHANGHAI, March 17, 2025 /PRNewswire/ — FinVolution Group (“FinVolution,” or the “Company”) (NYSE: FINV), a leading fintech platform... Read more.
FinVolution Group Reports Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results
-Full Year 2024 Transaction Volume reached RMB206.2 billion, up 6.1% year-over-year- -Full Year 2024 International Transaction Volume exceeded RMB10.1 billion, up... Read more.
TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025
TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening TaiMed Biologics will reshape HIV treatment management and... Read more.
3 Unmissable Sessions Driving the Future of Game Development at GDC 2025
Industry-leading sessions to explore platformer design, inclusive gaming, and blockchain’s evolving role. SAN FRANCISCO, March 17, 2025 /PRNewswire/ — Scalex... Read more.